Venus Remedies Limited has announced a pivotal milestone, securing its second incentive disbursement under the Government of India’s Production Linked Incentive (PLI) Scheme for Pharmaceuticals. This disbursement represents a substantial 75 percent of the total incentive earmarked for the fiscal year 2024-25.
Meeting PLI Criteria
This financial boost is a result of the company’s successful adherence to the investment, production, and sales metrics established by the PLI scheme. As a key player within the PLI 2.0 framework, Venus Remedies stands out among various pharmaceutical firms approved for this initiative.
Objectives of the PLI Scheme
The PLI scheme is designed to bolster domestic manufacturing capabilities and reduce reliance on imports. The incentives provided are expected to facilitate the company’s efforts in scaling up production and upgrading technologies, aligning with the overarching goals of enhancing India’s pharmaceutical landscape.
Leadership Insights
Saransh Chaudhary, President of Global Critical Care at Venus Remedies Limited and CEO of the Venus Medicine Research Centre, highlighted the importance of these disbursements. He emphasized that the financial support would significantly contribute to the company’s capacity expansion and investment in cutting-edge manufacturing technologies. Such advancements resonate with national priorities for healthcare and industrial growth.
The Atmanirbhar Bharat Initiative
Initiated under the Atmanirbhar Bharat campaign, the PLI scheme aims to catalyze domestic investments, amplify production, and improve global competitiveness across crucial manufacturing sectors, particularly in pharmaceuticals. With a total budget of ₹15,000 crore set for the period from 2020-21 to 2028-29, the scheme seeks to transform India’s pharmaceutical industry.
Positive Economic Trends
Recent government statistics reveal a remarkable shift in India’s pharmaceutical trade. The country transitioned from being a net importer of bulk drugs, registering a deficit of ₹1,930 crore in FY 2021-22, to achieving a surplus of ₹2,280 crore in FY 2024-25. Over the first three years of the PLI scheme, cumulative pharmaceutical sales surpassed ₹2.66 lakh crore, with exports contributing ₹1.70 lakh crore. Notably, domestic value addition reached an impressive 83.70 percent as of March 2025.
Manufacturing Capabilities of Venus Remedies
Headquartered in Panchkula, Venus Remedies Ltd specializes in the manufacture of fixed-dosage injectable formulations. The company operates manufacturing facilities in both India and Germany, ensuring a broad international presence. It has garnered approvals from numerous global regulatory authorities, reinforcing its commitment to maintaining high standards in production.
Research and Development Focus
In addition to its manufacturing prowess, Venus Remedies is home to the Venus Medicine Research Centre. This division is dedicated to pioneering research in antibiotics and therapies aimed at combating antimicrobial resistance. The center’s efforts are critical in addressing contemporary health challenges, making a substantial impact on global health.
Key Takeaways
- Venus Remedies received a 75% incentive disbursement under the PLI scheme for FY 2024-25.
- The PLI scheme aims to enhance domestic manufacturing and reduce import reliance in the pharmaceutical sector.
-
The company’s leadership emphasizes the role of this funding in facilitating capacity expansion and technological advancements.
-
India has transitioned from a bulk drug importer to a surplus producer within three years of the PLI scheme.
-
Venus Remedies continues to invest in research to combat antimicrobial resistance, positioning itself as a leader in pharmaceutical innovation.
In conclusion, Venus Remedies Limited’s recent achievement under the PLI scheme marks a significant stride toward enhancing India’s pharmaceutical manufacturing capabilities. This incentive not only reinforces the company’s growth trajectory but also contributes to the broader vision of self-reliance in the pharmaceutical sector. As the industry evolves, Venus Remedies stands poised to lead transformative changes, aligning with national health priorities and global competitiveness.
Read more → medicaldialogues.in